“Technological Convergence for Targeted and Patient-Centric Therapies”
- A major and accelerating trend in the global drug device combination market is the integration of advanced delivery technologies with biologics and pharmaceuticals to create highly targeted and patient-friendly therapies, enhancing treatment precision and adherence
- For instance, wearable injectors such as Amgen’s Neulasta Onpro enable patients to receive biologic drugs subcutaneously at home, eliminating the need for clinic visits. Similarly, YpsoMate autoinjectors are increasingly adopted for self-administration of chronic disease medications, offering convenience and ease of use
- These combination products leverage innovations such as micro-needles, smart sensors, and controlled-release mechanisms to optimize drug bioavailability and patient experience. Some smart inhalers now include digital tracking and Bluetooth connectivity, allowing for real-time monitoring of usage patterns and adherence
- The integration of digital health features with drug delivery devices enables remote patient management and personalized therapy adjustments. Devices equipped with sensors can collect data on dosage, timing, and adherence, which can then be analyzed through AI-enabled platforms for more informed clinical decisions
- Companies such as Insulet, Medtronic, and Enable Injections are actively developing next-gen drug device combinations that support minimal invasiveness, connected care, and higher therapeutic effectiveness in areas such as diabetes, oncology, and autoimmune diseases
- The growing demand for combination products that align with value-based healthcare and empower patients with self-administration options is reshaping drug delivery models and fostering widespread adoption across both developed and emerging healthcare systems
